Do polo-like kinase 1-targeting Chitosan Nanoparticles suppress the progression of hepatocellular carcinoma?
These findings indicate that PLK1-targeting nanoparticles exert considerable therapeutic merit and GCP/siRNA nanoparticles would be a valuable therapeutic carrier for HCC.
Avoiding cardiopulmonary bypass did not aid the reduction of atrial fibrillation at our institution.